Cue Biopharma appoints James Ahlers as CFO effective July 30, 2026

Cue Biopharma, Inc.

James Ahlers appointed CFO of Cue Biopharma effective July 30, 2026.
Base salary $450,000; eligible for discretionary annual bonus target of 45% of base salary.
Received inducement option for 51,000 shares at $30.40 and RSU for 25,500 shares, vesting quarterly over 4 years.
Previously served as CFO of Intarcia Therapeutics, consulting CFO at Danforth Advisors, and roles at Intensity Therapeutics and RenovoRx.
Severance: 9 months base plus prorated target bonus on qualifying termination; change-in-control triggers full equity acceleration.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Ahlers

Chief Financial Officer

CUE · Cue Biopharma, Inc.

Effective: 2026-07-30
Filed: August 3, 2026, 4:47 PM ET

On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Ahlers was appointed as Chief Financial Officer at Cue Biopharma, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”).

View on SEC.gov

Cue Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-330730

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.